Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
Glaucoma remains a leading cause of irreversible blindness worldwide, affecting millions of people and posing significant challenges for healthcare systems. Despite advancements in diagnostics and treatment, the complexity of the disease—characterized by its silent progression and multifactorial nature—demands a continuous evolution i...
The US Food and Drug Administration (FDA) recently provided a draft guidance on the application of artificial intelligence (AI) in regulatory decision making. By championing a balance between innovation and safety, this initiative highlights the significance of AI while upholding its rigorous scientific and regulatory standards. Entitled ‘Co...
The clinical trials landscape in 2025 is shaped by technological advancements, regulatory shifts, and a growing demand for innovative therapies. In our latest blog we explore key developments that are poised to leave a lasting impact on clinical trials. 1. AI and Machine Learning: Moving from Hype to Practical Applications Artificial Intelligence (...
Navitas Life Sciences has been at the forefront, sharing knowledge and driving impactful discussions. Here’s a roundup of our top 10 blogs for 2024 that captivated readers and enriched the life sciences community. 1. The Impact of Generative AI in Clinical Trials Generative AI, a specialized branch of Artificial Intelligence (AI), offers tra...
In a recent episode of The Gens & Associates Podcast, host Steve Gens engaged in a compelling discussion with Navitas Life Sciences' leaders: Marty Boom, Global Head of Regulatory & Safety, and Tris Nockles, Labeling Networks Lead. The conversation explored Navitas' innovative "nets" framework, the integration of AI and automation in regula...
As a leading CRO, Navitas Life Sciences consistently drives innovation in clinical trials, including oncology research, data sciences, regulatory affairs and pharmacovigilance. Our thought leaders have published a series of impactful articles that address critical industry challenges and advancements, showcasing our expertise and commitment to impr...
The second Medical Roundtable provided a rich platform for industry leaders to discuss strategies, innovations, and challenges in medical writing outsourcing. There were 11 attendees from across 8 companies, and the discussions emphasized the importance of strategic foresight, technological integration, and the optimal balance between insourcing an...
In the pharmaceutical industry, where data drives innovation and ensures regulatory compliance, sound data governance practices are critical. This is because data is at the heart of the most recent innovative breakthroughs, like Artificial Intelligence (AI), Machine Learning (ML) and Data Science (DS). Without a high-quality, well understood datase...
Diversity, equity, and inclusion (DEI) are no longer optional ideals for organizations. They are essential drivers of innovation, employee engagement, and sustainable growth. While many companies have made strides toward ensuring inclusive workplaces, the gap between intention and implementation remains significant. Addressing this gap requires not...
Thailand’s pharmaceutical and clinical trials industry is undergoing a transformative phase, positioning itself as a critical player in the global healthcare ecosystem. As the demand for innovative solutions grows, regulatory complexities, market dynamics, and therapeutic advancements converge to create a challenging yet promising environmen...